Investigational New Drugs

, Volume 34, Issue 4, pp 468–473 | Cite as

Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases

  • Michiro Takahashi
  • Kiyoshi HasegawaEmail author
  • Masaru Oba
  • Akio Saiura
  • Junichi Arita
  • Yoshihiro Sakamoto
  • Eiji Shinozaki
  • Nobuyuki Mizunuma
  • Yutaka Matsuyama
  • Norihiro KokudoEmail author


Summary of Background Data The effectiveness of adjuvant chemotherapy in patients with stage II/III colorectal cancer has been confirmed in various studies. However, no adjuvant chemotherapy for colorectal liver metastasis (CLM) classified to stage IV has been established. Objectives We conducted a phase 1 study of S-1 and oxaliplatin to determine the recommended dose (RD) in patients with CLM as adjuvant therapy in two institutes. Methods S-1 and oxaliplatin were administered from day 1 to day 14 of a 3-week cycle as a 2-h infusion every 3 weeks, respectively. The initial doses of S-1 and oxaliplatin were fixed to 80 mg/m2 and 100 mg/m2, respectively (level 1). We scheduled in the protocol a dose change of S-1 and oxaliplatin to level 2 (S-1: 80 mg/m2 and oxaliplatin: 130 mg/m2) or level 0 (S-1: 65 mg/m2 and oxaliplatin: 100 mg/m2) depending on the incidence of dose-limiting toxicity (DLT) at level 1 in six patients. Results Because DLT occurred in one among the initial six patients at level 1, the doses were increased to level 2 in the next six patients. At level 2, grade 3 leukopenia and neutropenia occurred in one (16.7 %) and two (33.3 %) patients, respectively, in the absence of non-hematological event. Because no DLT occurred at level 2, we suggest that the RD can be set to the level 2 dose. The median number of cycles delivered at RD was 8. The mean relative dose intensity of S-1 and oxaliplatin at RD was 0.90 and 0.63, respectively. Conclusion In a patient undergoing hepatectomy for CLM, 80 mg/m2 of S-1 and 130 mg/m2 of oxaliplatin are recommended as adjuvant therapy. A further study is required to confirm the efficacy and safety of this regimen on a larger scale.


Adjuvant therapy Colorectal liver metastases S-1 Oxaliplatin 


Compliance with ethical standards

Conflict of interest

Michiro Takahashi: No conflict of interest.

Kiyoshi Hasegawa: No conflict of interest.

Masaru Oba: No conflict of interest.

Akio Saiura: No conflict of interest.

Junichi Arita: No conflict of interest.

Yoshihiro Sakamoto: No conflict of interest.

Eiji Shinozaki: Honoraria- Takeda, Brystol Myers Squibb Japan, Taiho Pharmaceutical, Chugai Pharma, Ono Pharmaceutical.

Nobuyuki Mizunuma: No conflict of interest.

Yutaka Matsuyama: No conflict of interest.

Norihiro Kokudo: Honoraria- Taiho Pharmaceutical.


  1. 1.
    Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235(6):759–766CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247(1):125–135. doi: 10.1097/SLA.0b013e31815aa2c2 CrossRefPubMedGoogle Scholar
  3. 3.
    Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239(6):818–825 discussion 825-817CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352(26):2696–2704. doi: 10.1056/NEJMoa043116 CrossRefPubMedGoogle Scholar
  5. 5.
    Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29(11):1465–1471. doi: 10.1200/JCO.2010.33.6297 CrossRefPubMedGoogle Scholar
  6. 6.
    Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116. doi: 10.1200/JCO.2008.20.6771 CrossRefPubMedGoogle Scholar
  7. 7.
    Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25(16):2198–2204. doi: 10.1200/JCO.2006.08.2974 CrossRefPubMedGoogle Scholar
  8. 8.
    Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14(12):1208–1215. doi: 10.1016/S1470-2045(13)70447-9 CrossRefPubMedGoogle Scholar
  9. 9.
    Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, Bugat R, Lazorthes F, Bedenne L (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24(31):4976–4982. doi: 10.1200/JCO.2006.06.8353 CrossRefPubMedGoogle Scholar
  10. 10.
    Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A (2009) A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20(12):1964–1970. doi: 10.1093/annonc/mdp236 CrossRefPubMedGoogle Scholar
  11. 11.
    Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T (2000) Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 cooperative colorectal carcinoma study group. Br J Cancer 83(2):141–145. doi: 10.1054/bjoc.2000.1236 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H, Satoh A (2004) Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100(11):2355–2361. doi: 10.1002/cncr.20277 CrossRefPubMedGoogle Scholar
  13. 13.
    Mochizuki I, Takiuchi H, Ikejiri K, Nakamoto Y, Kinugasa Y, Takagane A, Endo T, Shinozaki H, Takii Y, Takahashi Y, Mochizuki H, Kotake K, Kameoka S, Takahashi K, Watanabe T, Watanabe M, Boku N, Tomita N, Matsubara Y, Sugihara K (2012) Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial. Br J Cancer 106(7):1268–1273. doi: 10.1038/bjc.2012.86 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Yoshida M, Ishiguro M, Ikejiri K, Mochizuki I, Nakamoto Y, Kinugasa Y, Takagane A, Endo T, Shinozaki H, Takii Y, Mochizuki H, Kotake K, Kameoka S, Takahashi K, Watanabe T, Watanabe M, Boku N, Tomita N, Nakatani E, Sugihara K (2014) S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). Ann Oncol 25(9):1743–1749. doi: 10.1093/annonc/mdu232 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23–30. doi: 10.1200/JCO.2004.09.046 CrossRefPubMedGoogle Scholar
  16. 16.
    de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947PubMedGoogle Scholar
  17. 17.
    Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26(12):2006–2012. doi: 10.1200/JCO.2007.14.9898 CrossRefPubMedGoogle Scholar
  18. 18.
    Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):1007–1016. doi: 10.1016/S0140-6736(08)60455-9 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, Hickish T, Butler R, Stanton L, Dixon E, Little L, Bowers M, Pugh S, Garden OJ, Cunningham D, Maughan T, Bridgewater J (2014) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the new EPOC randomised controlled trial. Lancet Oncol 15(6):601–611. doi: 10.1016/S1470-2045(14)70105-6 CrossRefPubMedGoogle Scholar
  20. 20.
    Kanemitsu Y, Kato T, Shimizu Y, Inaba Y, Shimada Y, Nakamura K, Sato A, Moriya Y (2009) A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan clinical oncology group study JCOG0603. Jpn J Clin Oncol 39(6):406–409. doi: 10.1093/jjco/hyp035 CrossRefPubMedGoogle Scholar
  21. 21.
    Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D (2014) Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncol 15(13):1481–1492. doi: 10.1016/S1470-2045(14)70486-3 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hong YS, Park YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Jo SJ, Lee JW (2012) S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol 13(11):1125–1132. doi: 10.1016/S1470-2045(12)70363-7 CrossRefPubMedGoogle Scholar
  23. 23.
    Sano T, Aiko T (2011) New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer 14(2):97–100. doi: 10.1007/s10120-011-0040-6 CrossRefPubMedGoogle Scholar
  24. 24.
    Yamada Y, Tahara M, Miya T, Satoh T, Shirao K, Shimada Y, Ohtsu A, Sasaki Y, Tanigawara Y (2008) Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer 98(6):1034–1038. doi: 10.1038/sj.bjc.6604271 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kim HS, Park MJ, Uhm JE, Lee Y, Lee HY, Kang EM, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS (2009) A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer. Int J Color Dis 24(11):1311–1316. doi: 10.1007/s00384-009-0758-3 CrossRefGoogle Scholar
  26. 26.
    Twelves C, Gollins S, Grieve R, Samuel L (2006) A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 17(2):239–245. doi: 10.1093/annonc/mdj023 CrossRefPubMedGoogle Scholar
  27. 27.
    Saiura A, Yamamoto J, Hasegawa K, Oba M, Takayama T, Miyagawa S, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Makuuchi M, Kokudo N (2014) A combination of oral uracil-tegafur plus leucovorin (uft + lv) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the uft/lv study. Drug Discov Ther 8(1):48–56. doi: 10.5582/ddt.8.48

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Michiro Takahashi
    • 1
    • 2
  • Kiyoshi Hasegawa
    • 1
    Email author
  • Masaru Oba
    • 1
  • Akio Saiura
    • 2
  • Junichi Arita
    • 1
    • 2
  • Yoshihiro Sakamoto
    • 1
  • Eiji Shinozaki
    • 3
  • Nobuyuki Mizunuma
    • 3
  • Yutaka Matsuyama
    • 4
  • Norihiro Kokudo
    • 1
    Email author
  1. 1.Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of MedicineUniversity of TokyoTokyoJapan
  2. 2.Department of Gastrointestinal SurgeryCancer Institute Hospital of the Japanese Foundation for Cancer ResearchTokyoJapan
  3. 3.Department of GastroenterologyCancer Institute Hospital of the Japanese Foundation for Cancer ResearchTokyoJapan
  4. 4.Department of BiostaticsUniversity of TokyoTokyoJapan

Personalised recommendations